ArticleBreast cancer research and treatment2025

Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2- early breast cancer: a discrete choice survey study.

Erica L Mayer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.